ONCBeOne Medicines AG

Healthcare
$377.78+19% 1Y

Is the business good?

Mixed

The checks split: nothing decisive, though margins widening.

1 good, 1 neutral, 2 without data
Margin direction, 3 years+123.8 pts

Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.

Where ROE comes from2% ROA

A balanced mix of margins, efficiency, and leverage. ROE 4% = margin × turnover × leverage.

All from derived.

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

Customers and suppliers

Who buys from ONC and who it buys from, as the companies report it.

19%of revenue comes from ASD Specialty Healthcare, the largest of 3 disclosed customers
Customerswho buys
Supplierswho it buys from

None disclosed.

A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; ONC’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.

Biotechnology

The closest names by size in the same industry

Compare peers
RVMD-0.37%
Revolution Medicines, Inc.
RPRX+0.16%
Royalty Pharma plc
ARGX-0.10%
argenx SE
ALNY-1.5%
Alnylam Pharmaceuticals, Inc.
ROIV-2.5%
Roivant Sciences Ltd.
GMAB+9.4%
Genmab A/S